The ZAMASA Foundation Medical Advisory Panel is comprised of recognised experts in multiple myeloma or associated fields. As membership of the Medical Advisory Panel necessarily changes overtime, the Board will seek to ensure that it is comprised of recognised experts in the following areas – multiple myeloma, B-cell malignancies, haematology, cancer immunotherapy and stem cell transplantation. Conjoint Associate Professor Dr John Moore of St Vincent’s Hospital and the Kinghorn Cancer Centre Sydney has kindly offered to chair the Medical Advisory Committee and work with the Committee to secure other members of the advisory committee following its establishment.
If you would like to support the ZAMASA Foundation please make a donation today
Dr John Moore graduated from Sydney University in 1989 and completed his residency and Haematology Advanced training at Royal North Shore Hospital. He was awarded Fellowship of the College of Physicians and Pathologists in 1997. He continued his training at the Westmead Children’s Hospital and subsequently became the Bone Marrow Transplant Coordinator at the Royal Free Hospital, London from 1997-1998. He returned to Australia in 1998 and completed a Doctorate of Medicine at St. Vincent’s Hospital whilst researching the role of Haematopoietic Stem cell Transplantation for Severe Rheumatoid Arthritis. He is currently a Senior Staff Specialist in the Haematology Department at St. Vincent’s Hospital and a Visiting Medical Officer at St. Vincent’s Private Hospital. He was the Chair of the Bone Marrow Transplant Committee of the Australian Leukaemia and Lymphoma Group (ALLG) from 2004-2006. He has been a member of the Executive of the ALLG from 2002-2006, Secretary from 2002-2004 and on the Safety and Data Monitoring Board from 2002-2006. He has been on the Medical Advisory Committee of the Leukaemia Foundation from 2002-2004. Dr Moore has been involved in clinical trials for the past ten years and is presently a Chief Investigator at St. Vincent’s Hospital in numerous clinical trials. His research interests include thymic differentiation of haematopoietic stem cells and clinical studies of haematopoietic stem cell transplant. He is a conjoint Senior Lecturer in Medicine at the University of New South Wales.
Prof Joshua was Head of Clinical and Laboratory Haematology at Sydney Cancer Centre, Head of Sydney Local Health District in Hematology, the Alan Ng Professor in Medicine at University of Sydney, and the Director of the Institute of Hematology, Royal Prince Alfred Hospital, until his retirement in 2014. He is presently Professor Emeritus in Hematology at the University of Sydney and Consultant Hematologist at RPAH. He is the chairman of the SLHD Blood Transfusion committee and a member of the CEC Blood Watch programme. He is chairman of the Blood Clinical and Scientific Advisory Committee (BCSAC) of the NSW Department of Health as well as Chairman of the National ARCBS Ethics committee .He is an advisor to the Commonwealth Department of Health for Clinical Haematology. Prof. Joshua received his BSC, MB BS, and his D Phil degrees from University of Sydney and University of Oxford. He is a fellow of The Royal Australasian College of Physicians and the Royal College of Pathologists of Australasia. Prof. Joshua is scientific advisor and member of the International Myeloma Foundation, Councillor on the International Myeloma Society and he serves on the editorial board of numerous journals. Prof. Joshua has a long standing interest in both basic and clinical research in Myeloma and has been supported by the National Health and Medical Research Council, Multiple Myeloma Research Foundation, International Myeloma Foundation, NSW State Cancer Council, Cancer institute of NSW , the University of Sydney Cancer Research Fund and the Sydney Foundation for Medical research. He has held sabbatical appointments as a visiting scholar at the University of Birmingham and the Dana Farber Cancer Centre at Harvard. Professor Joshua’s main research interest has been in the concept of host tumour control in myeloma and has published extensively on this topic. His group was the first to describe the presence of clonal T cells in myeloma and demonstrated their beneficial effect on prognosis. Currently his group is involved in the concept of active immunization as a potential immunological control mechanism in myeloma, which despite dramatic advances in therapy remains an incurable disease.
Dr Fiona Kwok is a clinical haematologist at Westmead Hospital. She obtained her medical degree from Sydney University and performed her Haematology Advanced Training at Royal Prince Alfred, Concord, Westmead and Royal North Shore Hospitals. She is a Fellow with the Royal Australasian College of Physicians and Royal College of Pathologists of Australasia. She is the Plasma Cell Disorder Clinical Lead at Westmead Hospital. She has contributed to the multiple myeloma protocol reviews for EVIQ. She is an experienced Principle Investigator in Multiple Myeloma trials. She has a clinical interest in rare plasma cell disorders, in particular light chain amyloidosis (AL). She has presented at national and international conferences on clinical studies in AL amyloidosis. She is a founding member of the Australian Amyloidosis Network and a member of the Westmead Amyloidosis Clinic.